Hemodialysis Patients May Benefit from Cholecalciferol Treatment Targeting High Level of 25(OH)D.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc and Parathyroid Hormone (PTH 1-84) in this observational study publication.

The aim of this observational prospective study was to assess the effect of cholecalciferol in achieving high-normal serum 25-hydroxycholecalciferol (25(OH)D > 75 ng/mL) levels and its impact on CKD-MBD biochemical markers, including 1,25-dihydroxycholecalciferol (1,25(OH)2D) and parathormone (PTH) in HD patients.

Why It Was Studied

(1) Background and Objectives: Vitamin D is implicated in the pathogenesis of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) in hemodialysis (HD) patients, including the development of secondary hyperparathyroidism (SHP).

While cholecalciferol supplementation is recommended for vitamin D deficiency correction, its impact on CKD-MBD remains inconsistent.

Who Took Part

According to the abstract, 22 patients were involved.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

What Was Measured

(1) Background and Objectives: Vitamin D is implicated in the pathogenesis of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) in hemodialysis (HD) patients, including the development of secondary hyperparathyroidism (SHP).

Baseline data on calcium, phosphate, 1-84 PTH, 25(OH)D, and 1,25(OH)2D serum levels were compared with the data when 25(OH)D > 75 ng/mL was targeted or when the highest 25(OH)D levels were noted.

The subject headings attached to it are Cholecalciferol, Renal Dialysis, Vitamin D, Vitamin D Deficiency, Parathyroid Hormone and Biomarkers.

The authors tagged it with the keywords 25-hydroxycholecalciferol, chronic kidney disease–mineral and bone disorder, hemodialysis and parathormone.

What This Means in Plain Language

This is an observational study of Vitamin D, K2, Magnesium and Zinc and Parathyroid Hormone (PTH 1-84) in 22 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2024 (Medicina (Kaunas, Lithuania)), a journal based in Switzerland.

More context: the Vitamin D, K2, Magnesium and Zinc compound page and the Parathyroid Hormone (PTH 1-84) compound page, all human trials.